CDP

Quick links to important sections

CDP

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of CDP

What is CDP? (Citicoline)

Property Description
Active ingredient Citicoline (Cytidine Diphosphate-Choline)
Form Tablets, Capsules, Oral/Injectable Solution
Pharmacological class Neuroprotectant, Nootropic, Psychoanaleptic
General purpose Support for cognitive health and neuronal structure
Origin Derivative (chemically synthesized, identical to endogenous metabolite)

Identity, Classification, and Composition

CDP is the accepted abbreviation for the compound Citicoline, which is the active pharmaceutical ingredient identified chemically as Cytidine 5'-diphosphocholine. Citicoline is classified primarily as a Neuroprotectant and a Nootropic under the Anatomical Therapeutic Chemical (ATC) classification system. The substance is a derivative that is chemically identical to the endogenous metabolite CDP-choline, a key substance found naturally in the body. This unique structural identity ensures high bioavailability for its targeted purpose. Citicoline is typically supplied as a single-ingredient product, available in common dosage forms including tablets, capsules for oral administration, and aqueous solutions for injection (Intravenous or Intramuscular), supporting a flexible route of administration.


General Purpose and Recognized Properties

Citicoline has established properties in the neuroprotective domain, with recognition for supporting neurological processes and membrane integrity. The overarching purpose of Citicoline is to offer fundamental support for overall brain function and cognitive health. This is achieved by the substance's primary mechanism principle: acting as an essential precursor for the synthesis of structural phospholipids, components that are vital for maintaining the integrity of neuronal cell membranes. It has an established role in aiding the maintenance of normal cognitive performance, which is a key differentiator from generic vitamin supplements.

What side effects are possible with CDP?

Possible Side Effects and Safety Information for CDP

This information describes the documented risks and adverse effects of CDP as organized in official government regulatory documents (e.g., FDA Prescribing Information, EMA SmPC). It is not a guide for use or a substitute for medical consultation.


Adverse Reaction Classification

Adverse reactions are formally classified by frequency and by the System-Organ Class (SOC) affected. The frequency categories used are based on international standards:

  • Very Common: Occurring in 1 out of 10 people or more.
  • Common: Occurring in less than 1 out of 10 but at least 1 out of 100 people.
  • Uncommon, Rare, and Very Rare: These describe reactions that occur with lower frequency, down to less than 1 out of 10,000 people.

Commonly reported adverse effects may include headache, nausea, and fatigue.


Serious Adverse Reactions and Safety Restrictions

Regulatory documents highlight specific Serious Adverse Reactions, which are rare but clinically significant. These may include severe hypersensitivity reactions (such as anaphylaxis) and significant effects on organs, such as severe hepatotoxicity or major hematologic abnormalities.

The label defines specific Contraindications, which are absolute prohibitions on using CDP, such as in patients with a known allergy to the active substance. Furthermore, mandatory safety monitoring is often required, such as periodic checking of liver function tests or specific blood counts, as detailed in the official safety information.


Population-Specific Safety Notes

The official label contains specific safety statements for certain groups. For example, use may be contraindicated or require dosage adjustment in patients with severe hepatic (liver) or renal (kidney) impairment. Separate regulatory statements also address the established risks and safety profile for use during pregnancy and lactation, and in pediatric or older adult patient populations.

Overdose and Emergency Response

Overdose and When to Seek Help

This section summarizes officially documented information regarding chlordiazepoxide (CDP) overdose, based strictly on regulatory sources.


Documented Overdose Manifestations

Overdose presentations range from mild to severe Central Nervous System (CNS) depression. Initial signs commonly include somnolence, confusion, ataxia (impaired coordination), and diminished reflexes.


Critical Outcomes and Emergency Action

Severe, potentially life-threatening outcomes include respiratory depression, profound hypotension, and coma. The risk of these severe effects is significantly increased if CDP is combined with other CNS depressants, such as alcohol or opioids.

Immediate medical attention is mandatory if an overdose is suspected and particularly if shallow or slowed breathing, or cessation of breathing, occurs. Emergency response involves securing the airway, monitoring respiration, pulse, and blood pressure, and establishing intravenous access.


Management and Antidote Information

General management focuses on supportive measures. Procedures such as immediate gastric lavage or administration of activated charcoal may be employed. If hypotension is present, it may be managed using pressor agents (e.g., norepinephrine).

Flumazenil, a specific benzodiazepine-receptor antagonist, may be used as an adjunct to reverse sedation. However, its use requires careful monitoring for resedation and respiratory depression and carries a risk of precipitating withdrawal symptoms, including seizures, in dependent individuals.

Therapeutic Uses of CDP

What CDP Treats: Main Uses and Benefits

Citicoline (CDP) is primarily used for the supportive management of neurological and cognitive symptoms and is applied across therapeutic domains involving neurological and cognitive function.

This medication is relevant for easing symptoms in chronic brain conditions such as vascular dementia, long-term consequences of stroke, and craniocerebral injury. It is also applied in conditions involving specific neurological strain, including supportive assistance for symptoms linked to organ-specific functional stress in glaucoma and non-motor symptoms associated with Parkinson's disease.

Therapeutic support is relevant for managing symptom clusters that interfere with daily functioning, such as impaired memory, disorientation, and difficulty with concentration. For patients experiencing these challenges, the support contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.

“This supportive relief may assist with managing symptoms that create noticeable functional strain across specialized therapeutic domains.”


Quick Fact: Support for Cognitive Decline Symptoms

CDP is commonly used in clinical settings that involve unstable symptom patterns or episodes of acute, disruptive neurological events, providing assistance during recovery phases and contributing to improved day-to-day comfort.

Eligibility and Restrictions for Use

The eligibility profile for Citicoline (CDP) is strictly defined by regulatory authorities and establishes clear constraints on who can and cannot use the medicine.

Category Official Regulatory Status
Absolute Contraindications Use is contraindicated in patients with documented hypersensitivity to Citicoline or any of its components. It is also prohibited for patients exhibiting marked hypertonia of the parasympathetic nervous system.
Age-Related Eligibility Adults are the primary eligible population, and older adults are generally eligible under standard labeled conditions. For children and adolescents (under 18 years), use is not recommended because the safety and efficacy of the drug have not been established.
Conditional/Restricted Use Use during pregnancy and lactation is not recommended due to insufficient safety data, and is permitted only when the potential benefit is determined to outweigh the risk. The medicine requires caution when administered to patients with conditions like a history of depression or Parkinson's disease.

Connection to the overall eligibility profile

Regulatory documents clearly define absolute exclusions based on patient conditions and hypersensitivity. For special populations, eligibility is limited by a classification of use not established (pediatric) or insufficient data (pregnancy/lactation), requiring highly restricted or conditional approval rather than general use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Citicoline (CDP) has a defined interaction profile based strictly on official regulatory prescribing information. The known interactions primarily involve pharmacodynamic effects and specific administration restrictions, with no complex pharmacokinetic interactions such as CYP or transporter-based effects being formally documented in official regulatory labels.


Documented Interaction Patterns

Formal Contraindicated Combination

Co-administration with preparations containing Meclofenoxate (also known as Clophenoxate) is strictly prohibited as a formal contraindication. This substance must not be administered concurrently with Citicoline, a restriction formally stated in product labels.


Pharmacodynamic Enhancement

A specific pharmacodynamic interaction is documented with the anti-Parkinsonian agent L-Dopa (Levodopa). Co-administration results in the enhancement of L-Dopa’s effects.


Substance Administration Restriction

Official regulatory documents include a constraint regarding lifestyle substances, stating that alcohol should not be consumed while the Citicoline preparation is being used. This restriction is included to maintain appropriate conditions during use.


These statements represent the entire, officially documented interaction profile, defining how the product interacts with specific substances according to governmental health authorities.

Mechanism of Action

How CDP Works: Mechanism of Action

Cell Membrane Structural Support

The molecule acts as a precursor to phosphatidylcholine (PC), a primary structural component of neuronal cell membranes, by stimulating the enzyme CTP-phosphocholine cytidylyltransferase (CCT). This mechanism maintains the structural integrity and viability of neuronal cells.


Enhanced Neurotransmitter and Metabolic Function

CDP-choline provides the precursor choline used in the synthesis of the neurotransmitter acetylcholine. Furthermore, its incorporation into membranes helps restore the activity of energy-critical enzymes, including Na^+/ K^+ ATPase. This dual action enhances neuronal cholinergic signaling and cellular bioenergetics through ATP synthesis.


Attenuation of Degradation Cascades

By attenuating the activity of membrane-degrading enzymes such as Phospholipase A2 ( PLA2), the mechanism limits the release of free fatty acids and subsequent destructive cascades. This action supports the physical maintenance of neural tissue structure.

Dosage and Administration Information

Administration Guidelines for Citicoline (CDP)

Citicoline (CDP) is administered according to parameters that define the permitted routes of delivery, dosage ranges, and specific procedural requirements. This compound is available in various dosage forms, including tablets, capsules, and a solution for parenteral use (Intramuscular or Intravenous).


Administration Routes and Dosing

The primary routes of administration are oral and parenteral (injection). The standard adult daily dosage generally falls within the range of 500 mg to 2000 mg (2 g) total per day. The precise dose and the duration of the treatment course are determined based on the severity of the neurological condition being managed. Oral intake allows for flexibility and can be taken with or between meals.

Administration Aspect Instruction
Daily Dosage Range 500 mg to 2000 mg (2 g)
Frequency Once daily or in divided doses (e.g., twice daily)
Elderly Dosing No specific adjustment is required

Procedural Requirements

Specific technical instructions govern the use of the injectable form. Direct intravenous (IV) injection is administered very slowly, over a period of approximately 3 to 5 minutes. Separately, Citicoline should not be administered concurrently with medicinal products containing meclofenoxate.

Recent Clinical Evidence

Research evidence / Overview of Studies for CDP


Evidence for Use in Acute Ischemic Stroke (AIS)

Research has been studied for Citicoline in the context of acute ischemic stroke (AIS). The main body of evidence comes from Randomized Controlled Trials (RCTs) and systematic reviews. These studies explored how patients with moderate to severe neurological deficits fared when they received the compound shortly after a stroke event. Researchers primarily monitored outcomes reflecting functional recovery and daily functioning, using standardized scales to compare patient groups.

Early pooled findings describe patterns that included reporting a comparison of the proportion of patients achieving low disability scores compared to placebo. However, the outcomes from the largest, most recent, and highest-quality individual RCTs have been mixed. These large trials often reported no statistically significant difference in their primary goals. This variability across studies means the overall evidence on the role of Citicoline in the acute phase of stroke, alongside modern care methods, is complex.

Evidence for Chronic Cognitive Impairment

Citicoline was evaluated in research settings involving conditions characterized by functional limitations, such as vascular cognitive impairment (VCI) and cognitive problems that may follow a stroke. These studies explored the study endpoints related to specific measures of attention and daily functioning over periods longer than the acute phase, typically including older adults with established cognitive challenges.

Research describes patterns of stability or change in specific cognitive areas. These findings contribute to the broader evidence landscape by describing patterns of stability or change in these cognitive areas in the observed populations.

Areas of Research Uncertainty and Gaps

Certainty remains low for a clear and definitive role in some acute settings due to the inconsistency of findings between different major trials. Furthermore, the long-term effects are not fully established, as most research has concentrated on short-term or intermediate outcomes, typically between three and nine months. This means evidence provides limited insight into the durability of any observed changes. Data for specific patient subgroups, such as children or individuals with complex comorbid conditions, remains insufficient.

Key Studies & References

  1. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial)
  2. Citicoline for the Management of Patients with Traumatic Brain Injury in the Acute Phase: A Systematic Review and Meta-Analysis

Frequently Asked Questions (FAQ)

Common questions about CDP (FAQ)


Q: Is it normal to feel very sleepy when first starting CDP?

Official product information indicates that drowsiness and fatigue have been reported as potential side effects. The medication may also cause disorientation or confusion. If a person experiences excessive sleepiness or significant changes in alertness, they may consider consulting with a healthcare professional.


Q: Does CDP build up in your system over time?

Regulatory information indicates that Citicoline is rapidly absorbed and utilized by the body, with its components incorporated into tissues and used in biosynthetic pathways. The elimination of its breakdown products has been reported with two distinct half-lives: one short (around 3.5 hours) and one long (around 125 hours), reflecting how long the medication’s components are present in the body’s chemistry.


Q: Does CDP affect a person's driving ability or reaction time?

Yes, official prescribing information advises that this medication may affect a person's ability to drive or operate machinery. This is because adverse effects such as drowsiness, disorientation, and dizziness have been reported. Due to these potential effects, caution is generally advised before engaging in activities that require full mental alertness.


Q: Can taking CDP cause upset stomach or other digestive issues?

Gastrointestinal discomfort is among the common adverse effects reported in official regulatory documents. These may include mild symptoms such as stomach pain, nausea, and diarrhea. These issues are generally reported as mild.


Q: How long does the effect of one dose of CDP typically last?

Official prescribing information does not specify a precise duration of effect for a single dose. Citicoline is primarily studied for its supportive role in neurological processes over a treatment course, and some research recommends longer treatment periods to observe intended benefits.


Q: Why do some people feel dizzy or unsteady on their feet while taking CDP?

Dizziness is listed as a potential adverse drug reaction in official product information. This effect may cause a person to feel unsteady. A healthcare provider can be consulted if dizziness is persistent or severe.


Q: Can CDP be taken with vitamins or mineral supplements?

Regulatory documents emphasize the importance of communicating with a healthcare provider about all substances being used. This includes prescription medicines, over-the-counter products, and supplements such as vitamins or minerals, to allow for a full review of the possible interaction profile.


Q: How does CDP interact with common pain relievers like ibuprofen?

Official drug labels state that potential interactions may occur with various medications, including certain pain relievers. It is standard practice to inform a healthcare provider about any common pain relievers or other non-prescription drugs being taken before beginning treatment with CDP.


Q: Are there any specific foods or drinks to avoid while on CDP?

Yes, official regulatory documents specifically advise patients to avoid the consumption of alcohol while using this medication. There are no other explicit food or drink restrictions listed.


Q: Is it possible to have a paradoxical reaction to CDP (e.g., increased anxiety)?

Some official drug information sources list anxiety as one of the potential side effects of Citicoline. Any unexpected or worsening symptoms are grounds for consulting with a healthcare professional.


Q: What is the typical half-life of CDP in the body?

Pharmacokinetic studies reported in official documents indicate that the elimination half-life of Citicoline's breakdown products has two components. The initial half-life is around 3.5 hours, and the terminal half-life is approximately 125 hours, showing how long the components are present in the system.


Q: Does CDP have a different effect if taken on an empty stomach?

The oral forms of the medication are noted in prescribing guidelines as being able to be taken with or between meals. This indicates flexibility in timing, and official information does not specify a clinically significant difference in effect based on taking the dose on an empty stomach.


Q: Are there different forms of the CDP medication (tablet, capsule, liquid)?

Yes, this medication is typically available in several forms. These include oral dosage forms such as tablets and capsules, as well as an injectable solution for administration by a healthcare professional.


Q: Do you need to gradually stop taking CDP, or can you just quit?

Official instructions state that this medication should not be discontinued without consulting with a prescribing healthcare professional. They can provide specific guidance on stopping treatment if necessary.


How should CDP be stored and disposed of?

How to Store and Dispose of Citicoline (CDP)

The official storage requirements for Citicoline define specific environmental and handling constraints. The product must be stored at a temperature not exceeding 30 C and protected from light.


Official Conditions

Item Requirement
Temperature Store below 30 C.
Protection Protect from light; do not freeze liquid formulations.
Container Keep in the original container and tightly closed.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Citicoline must not be disposed of via general household trash or flushed down a toilet. Disposal must be carried out in accordance with local regulations or by returning the medicine to a pharmacist to ensure environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of CDP found in:

A-Z Index: